INTERACTION OF INTRAVENOUS DILTIAZEM WITH LOVASTATIN

这项研究将评估一种常用的钙拮抗剂， 即地尔硫卓，已知具有阻断细胞色素的能力 P450 3A4，这在之前的研究中已经显示出导致 当口服洛伐他汀时，药物相互作用也会产生同样的结果 肠外途径给药时的相互作用。该方案将评估 洛伐他汀是否对药物动力学相互作用敏感 地尔硫卓对活性基团形成的影响 静脉注射。 这项研究的具体目的是确定观察到的 地尔硫卓与洛伐他汀的相互作用发生在肠间水平 或者在肝脏里。静脉注射地尔硫卓将有助于回答这个问题 问题是通过绕过肠道细胞色素P450 3A4。

This study will assess whether or not a commonly used calcium antagonist, namely diltiazem, that is known to have the capacity to block cytochrome P450 3A4, and which has been shown in out previous study to result in a drug interaction with lovastatin when given orally will produce the same interaction when given by the parenteral route. The protocol will evaluate whether lovastatin is susceptible to pharmacokinetic interactions that effect the formation of active moieties when diltiazem is given intravenously. The specific aims of the study are to determine whether the observed interaction of diltiazem with lovastatin, occurs at the interstinal level or in the liver. Intravenous therapy with diltiazem will help answer this question by bypassing the intestinal cytochrome P450 3A4.